Given that mutant p53 proteins engage various mechanisms to evade anti-tumor immunity—including disruption of antigen presentation and modulation of inflammatory signaling pathways [24]—we hypothesized that different p53 mutants might adopt distinct immune evasion strategies, potentially revealing mutation-specific vulnerabilities amenable to therapeutic targeting. Here, TP53 is linked to neoplasm.